CTIC News 2.75 05/14/2014 04:41:09 Cell Therapeutics (CTIC)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cell Therapeutics (CTIC) 2.75 $CTIC

Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack
at The Street - Fri May 09, 5:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Technical Coverage on Biotech Stocks -- Research on Celgene, Cell Therapeutics, Geron, and BioMarin Pharma
PR Newswire - Tue May 06, 8:15AM CDT
The trading session on Monday, May 05, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,530.55, up 0.11% and the NASDAQ Composite closed at 4,138.06, up 0.34%. The S&P 500 finished the day 0.19% higher at 1,884.66. The gains were broad based as eight out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day 0.56% higher at 672.57, and the index has gained 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: Celgene Corporation (NASDAQ: CELG), Cell Therapeutics Inc. (NASDAQ: CTIC), Geron Corporation (NASDAQ: GERN) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free technical research on CELG, CTIC, GERN and BMRN can be downloaded upon signing up at:

Cell Therapeutics Reports First Quarter 2014 Financial Results
PR Newswire - Tue Apr 29, 3:01PM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the first quarter ended March 31, 2014.

Furiex Pharmaceuticals (FURX) Surges: Stock Moves 28.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 8:21AM CDT
Furiex Pharmaceuticals, Inc. (FURX) was a big mover last session, as the company saw its shares rise by roughly 29% on the day.

PIXUVRI(R) Launched In UK For Adult Patients With Multiply Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
PR Newswire Europe - Tue Apr 29, 3:03AM CDT
- First and Only Approved Monotherapy in the EU for this Patient Population -

PIXUVRI® Launched In UK For Adult Patients With Multiply Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
PR Newswire - Tue Apr 29, 12:30AM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the launch of PIXUVRI® (pixantrone), the first new treatment for adult patients in the United Kingdom (UK) with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), at the 54th annual scientific meeting of the British Society for Haematology.

Cell Therapeutics to Report First Quarter 2014 Financial Results on April 29, 2014
PR Newswire - Tue Apr 22, 12:30AM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its first quarter 2014 financial results on Tuesday, April 29, 2014, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m. PDT). Access to the event can be obtained as follows:

Shorts Are Piling Into These Stocks. Should You Be Worried?
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 21, 3:46PM CDT
The best thing about the stock market is that you can make money in  either direction . Historically, stock indexes tend to trend upward over the long term. But when you look at individual stocks, you'll find plenty that lose money over the long...

Pacira Pharmaceuticals (PCRX) Soars: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 8:21AM CDT
Pacira Pharmaceuticals, Inc. (PCRX) was a big mover last session, as the company saw its shares rise by over 11% on the day.

Insider Trading Alert - CTIC, KR And IBKR Traded By Insiders
at The Street - Mon Mar 31, 9:45AM CDT
Stocks with insider trader activity include CTIC, KR and IBKR

Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday

Insider Trading Research -- Alerts for Ariad Pharmaceuticals, Cell Therapeutics, Staples, Sirius XM, Facebook, and Bank of America
PR Newswire - Tue Mar 25, 7:55AM CDT
Today, Insiderslab.com released the latest insider trading research for Ariad Pharmaceuticals (NASDAQ:ARIA), Cell Therapeutics (NASDAQ:CTIC), Staples (NASDAQ:SPLS), Sirius XM (NASDAQ:SIRI), Facebook (NASDAQ:FB), and Bank of America (NYSE:BAC). US stock investors can access these reports through the links below, including stock performance, insider trading signals, and visual results.

Stock to Watch: Cell Therapeutics Down 5.5% (CTIC)
Comtex SmarTrend(R) - Mon Mar 24, 10:11AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's worst performing low-priced stocks, down 5.5% to $3.60 on 1.3x average daily volume. Cell Therapeutics has traded 6.6 million shares thus far today, vs. average volume of 5.0 million shares per day. The stock has underperformed the Dow (-5.5% to the Dow's -0.2%) and underperformed the S&P 500 (-5.5% to the S&P's -0.6%) during today's trading.

What's Next for Geron and Imetelstat?
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 19, 11:05AM CDT
It's been a volatile year for clinical-stage cancer-focused biopharmaceutical company Geron , whose shares moved lower by 60% last week following the announcement of a full clinical hold of its only clinical compound, imetelstat, and rocketed...

Initiation of Clinical Trials, Completed Acquisitions, Financial Results, and Earnings Release Schedules - Analyst Notes on Cell Therapeutics, Intrexon, Chimerix, Receptos, and Revance Therapeutics
PR Newswire - Tue Mar 18, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Cell Therapeutics, Inc. (NASDAQ: CTIC), Intrexon Corporation (NYSE: XON), Chimerix, Inc. (NASDAQ: CMRX), Receptos, Inc. (NASDAQ: RCPT), andRevance Therapeutics, Inc. (NASDAQ: RVNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Investor-Edge.com Most Active Equities Watch List: Cell Therapeutics, Yandex, Himax Technologies, and CytRx
PR Newswire - Fri Mar 14, 7:54AM CDT
The trading session on Thursday, March 13, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,108.89, down 1.41% and the NASDAQ Composite closed at 4,260.42, down 1.46%. The S&P 500 finished the session 1.17% lower at 1,846.34. The losses were broad based as nine of ten sectors ended the session in negative. Investor-Edge.com looks at some of the equities which were most active during the session. These include Cell Therapeutics Inc. (NASDAQ:CTIC), Yandex N.V. (NASDAQ:YNDX), Himax Technologies Inc. (NASDAQ:HIMX), and CytRx Corp. (NASDAQ:CYTR). Free research on these four companies can be accessed at:

Geron: FDA Suspends Key Myelofibrosis Drug Due to Liver Safety Concerns
at The Street - Wed Mar 12, 8:57AM CDT
The FDA's clinical hold placed on Geron's imetelstat means all clinical trials are suspended.

Insider Trading Alert - CTIC, TCBI And FCS Traded By Insiders
at The Street - Mon Mar 10, 12:16PM CDT
Stocks with insider trader activity include CTIC, TCBI and FCS

Cell Therapeutics to Present at the 26th Annual ROTH Conference
PR Newswire - Wed Mar 05, 12:30AM CST
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that management will present at the ROTH Capital Partners 26th Annual Conference on Tuesday, March 11 at 11:30 a.m. PST/2:30 p.m. EST/7:30 p.m. CET in Dana Point, CA.

Cell Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Tue Mar 04, 3:00PM CST
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2013.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Zensar’s AI Forum Puts Operations Before the AI Hype

Updated Category News Views 47

Johannesburg’s AI conversation seems to be shedding its costume jewelry at last. Zensar’s invitation-only CIS Converge 2026 forum, held on November 20, put the attention where it belongs: not on breathless demos, but on whether companies can turn AI into sturdier operations, better customer experiences, and something resembling a measurable return. That is a healthier...

Continue Reading
Lennar Lawsuit Puts Land-Light Claims Under a Microscope

Updated Category News Views 142

Three ugly selloffs, a murky land-bank story, and a fresh securities complaint have turned Lennar into the sort of holding that makes shareholders reread every footnote. The lawsuit is not a verdict, and the allegations remain unproven, but the timeline is nasty enough that investors in NYSE:LEN should not shrug it off as ordinary housing-cycle turbulence. The Dates...

Continue Reading
Anduin Opens Its Investor Portal Beyond Early Users

Updated Category News Views 30

Private-market paperwork has long been a swamp of portals, PDFs, email chains, and somebody chasing down a wire change at the worst possible moment. Anduin is taking a swing at that mess by opening its Investor Portal to all customers after building it with leading asset managers and operating it with their investors. The pitch is sensible: give limited partners one...

Continue Reading
Yangtze Documentary Frames a Decade of Economic Change

Updated Category News Views 54

A fish, a kilowatt-hour, a microchip, and a shipping container walk into the same economic story—well, not literally, thank goodness—and that is the unusual wager behind CCTV4’s upcoming Our Home, Our Yangtze. Announced in Beijing on November 19, 2026, the four-part documentary aims to recount a decade of change across the Yangtze River Economic Belt without leaning...

Continue Reading
Intel Investors Face January 12 Lead Plaintiff Deadline

Updated Category News Views 156

A Narrow Calendar Window Has Opened Intel holders have another legal deadline to put on the fridge, and this one is not a casual housekeeping item. A securities class action has been filed in the Northern District of California on behalf of investors who bought or acquired Intel shares between July 23, 2026, and October 29, 2026. The deadline to seek appointment as lead...

Continue Reading
BreakBio's New CSO Adds Vaccine Trial Credibility in Cancer

Updated Category News Views 144

Personalized cancer vaccines have no shortage of grand promises; seasoned clinical operators are the rarer commodity. That is why BreakBio's appointment of Dr. Greg Lizée as chief scientific officer deserves a closer look, even if nobody should confuse an executive hire with clinical validation. BreakBio is private, its lead program remains in development, and cancer...

Continue Reading
SAP Execution Can Steady Operations Beyond Spreadsheets

Updated Category News Views 114

Spreadsheets breed little kingdoms, and SAP is often left outside the gate. That is the operational mess Martin Rowan, managing partner at Reveal USA, Inc. in Naperville, is taking aim at in a Nov. 19, 2026 HelloNation feature. His central point is not terribly glamorous, but it is dead right: a company gets less stable when it uses SAP to explain yesterday's results...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 193

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
AI Shopping Answers Are Becoming Retail's New Shelf

Updated Category News Views 24

Retail’s front door is quietly being moved by a machine, and plenty of big chains appear to be staring at the old entrance. Bain’s latest work lands on an uncomfortable point: owning market share does not guarantee a retailer gets named when an AI assistant answers a shopper’s question. That ought to rattle management teams more than the usual holiday-season...

Continue Reading
Baker Tilly Breach Raises Hard Questions on Vendor Risk

Updated Category News Views 121

A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...

Continue Reading

Top 5 Most Recently Viewed Articles

Eagle Pharmaceuticals Board Advances Rights Plan for Shareholders

Updated Category News Views 231

Eagle Pharmaceuticals Board Extends Rights Plan Duration Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) has announced an update regarding its stockholder rights plan. The Board of Directors has approved an important amendment to the existing limited duration rights plan, extending its validity for one additional year, until October 30, 2026. Reason for the Amendment This...

Continue Reading
How Trump's Immigration Policies Could Impact US Growth

Updated Category News Views 338

Trump's Immigration Policies and Economic Growth Donald Trump's approach to immigration is likely to influence the rate of migration into the United States significantly, implying a potential slowdown in the nation's economic growth. Analysts at Piper Sandler have expressed concerns that the upcoming policies could lead to a meaningful deceleration in migration rates that...

Continue Reading
Sonder Holdings Faces Nasdaq Compliance Challenges Ahead

Updated Category News Views 142

Sonder Holdings Faces Nasdaq Compliance Challenges Sonder Holdings Inc. (NASDAQ: SOND), a cutting-edge hospitality company known for its tech-enhanced accommodations, recently received a formal notification from Nasdaq regarding a compliance issue. This is primarily due to the company's delay in filing its Q3 financial report for the period ending September 30, 2024. The...

Continue Reading
Join Us for the 2024 AvaSure Symposium Celebrating Virtual Care

Updated Category News Views 90

Overview of the 2024 AvaSure Symposium Healthcare professionals from across the country are preparing to convene for the 2024 AvaSure Symposium. This event will focus on the significant impact of AI-driven virtual care platforms on improving patient outcomes, enhancing staff satisfaction, and ensuring a healthy return on investment (ROI). Event Information The upcoming...

Continue Reading
Revolutionizing Scientific Communication: Stempad's Winter Update

Updated Category News Views 282

Revolutionizing Scientific Communication: Stempad's Winter Update Stempad, the world's first alternative for pen-and-paper scientific writing, has excited the academic community with the announcement of its new winter features. This innovative tool supports students, educators, and researchers in STEM fields, ensuring they have a seamless solution for effective scientific...

Continue Reading